公开(公告)号：US20240409611A1

公开(公告)日：2024-12-12

申请号：US18817735

申请日：2024-08-28

Applicant: Amgen Inc.

Inventor： Yael WEXLER-COHEN ,  Robert Matthew FESINMEYER ,  Monica Michelle GOSS ,  Sekhar KANAPURAM ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: C07K14/71 ,  A61K9/00

Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.

公开(公告)号：US20250082726A1

公开(公告)日：2025-03-13

申请号：US18959137

申请日：2024-11-25

Applicant: AMGEN INC.

Inventor： Yael WEXLER-COHEN ,  William J. CALLAHAN ,  Robert Matthew FESINMEYER ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34

Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.

公开(公告)号：US20220119526A1

公开(公告)日：2022-04-21

申请号：US17424547

申请日：2020-01-27

Applicant: Amgen Inc.

Inventor： Subramanian GUHAN ,  Malhar R. AMBHAIKAR ,  Vincent CHAI ,  Sai Chakradhar PADALA ,  Nitin RATHORE ,  Zane SAREMI ,  Kenneth SHOEMAKER ,  Benjamin J. TILLOTSON ,  Balakumar THANGARAJ ,  Philip CLARK ,  Ashish SHARMA ,  Hann-Chung WONG ,  John E. THORUP

IPC: C07K16/28 ,  C07K1/36 ,  A61K47/26

Abstract: A biologics manufacturing process that connects the drug substance and drug product processes into an integrated, continuous process.

公开(公告)号：US20200338164A1

公开(公告)日：2020-10-29

申请号：US16764463

申请日：2018-11-16

Applicant: Amgen Inc.

Inventor： Yael WEXLER-COHEN ,  William J. CALLAHAN ,  Robert Matthew FESINMEYER ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34 ,  A61K47/02

Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.

公开(公告)号：US20230025418A1

公开(公告)日：2023-01-26

申请号：US17932255

申请日：2022-09-14

Applicant: Amgen Inc.

Inventor： Yael WEXLER-COHEN ,  Robert Matthew FESINMEYER ,  Monica Michelle GOSS ,  Sekhar KANAPURAM ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: C07K14/71 ,  A61K9/00

Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.

公开(公告)号：US20200255496A1

公开(公告)日：2020-08-13

申请号：US16647902

申请日：2018-09-17

Applicant: Amgen Inc.

Inventor： Yael WEXLER-COHEN ,  Robert Matthew FESINMEYER ,  Monica Michelle GOSS ,  Sekhar KANAPURAM ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: C07K14/71 ,  A61K9/00

Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEG-FR-Fc fusion protein is aflibercept.